Evaluation of Remnant Cholesterol Levels and Monocyte-to-HDL-cholesterol Ratio As Predictors of Coronary Artery Disease Severity in Patients with Acute Coronary Syndrome

Launched by ASSIUT UNIVERSITY · Dec 26, 2024

Keywords

ClinConnect Summary

This clinical trial is looking to understand how certain cholesterol levels in the blood can help predict the severity of heart disease in patients who are experiencing acute coronary syndrome (ACS), a serious condition that includes heart attacks. Specifically, the study will measure two things: remnant cholesterol levels and the ratio of monocytes (a type of white blood cell) to HDL cholesterol (often referred to as "good" cholesterol). Researchers believe that these measurements could help identify which patients might face more severe health issues during their hospital stay or have major heart-related problems within 45 days after their initial treatment.

To participate in this study, individuals must be between the ages of 65 and 74 and have been diagnosed with acute coronary syndrome, requiring a procedure called primary PCI (a type of heart surgery). However, people who have previously taken certain cholesterol-lowering medications (statins) or have serious kidney problems won’t be eligible. The trial is not yet recruiting participants, but it aims to gather important information that could improve how doctors assess and treat patients with heart issues, leading to better outcomes for those affected by acute coronary syndrome.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with acute coronary syndrome presented to ER of Assiut university hospital scheduled for primary PCI and able to provide informed consent.
• Exclusion Criteria:
• • Patients on previous statin therapy.
• • Patients with severe renal dysfunction (creatinine clearance \<30 mL/min) or other contraindications to PCI.
• • Patients with missed data or who couldn't be followed up